Advertisement Pharmaceutical Business review - Page 41 of 5265 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
March 23, 2026

BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma

Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) has received approvals for two new indications in classical Hodgkin Lymphoma (cHL) from the US Food and Drug Administration (FDA) and the European Commission (EC), expanding its use for both paediatric and adult patients.

The EC approval is based on the Phase II CheckMate-744 trial in classical Hodgkin Lymphoma patients. Credit: Saiful52 / Shutterstock.com.